Investor Presentation
June 2020
Presentation June 2020 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS - - PowerPoint PPT Presentation
Investor Presentation June 2020 DISCLAIMERS AND FORWARD-LOOKING STATEMENTS Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the
June 2020
Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” “could,” “appears,” “shall,” “target,” “contemplated,” “predicts,” “potential,” “continue” and variations and negatives of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have
statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, statements about our future financial performance and ability to achieve profitability, including our revenue, costs of revenue and operating expenses; our anticipated growth and growth strategies and our ability to effectively manage that growth; the sufficiency of our cash, cash equivalents and investments to meet our liquidity needs; our ability to maintain the security and availability of our platform; our predictions about our industry (including total addressable market) and market trends for healthcare technology solutions; our ability to attract, retain and cross-sell to healthcare provider clients; our ability to maintain renewal rates for healthcare provider clients; our ability to maintain, protect and enhance our intellectual property; our ability to comply with modified or new laws and regulations applying to our business; the increased expenses associated with being a public company; and our outstanding debt under our credit facility, as well as those set forth in our Annual Report on Form 10-K that was filed with the SEC on April 23, 2020 and our other filings with the U.S. Securities and Exchange Commission, including “Risk Factors” sections contained therein. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. This presentation may include certain non-GAAP financial measures as defined by SEC rules. We have provided a reconciliation of those measures to the most directly comparable GAAP measures, which is available in the Appendix.
DISCLAIMERS AND FORWARD-LOOKING STATEMENTS
2
3
How we do it: Software-as-a-Service (SaaS) platform to manage the patient intake process and an integrated patient payments solution for secure processing of patient payments
~1,600 healthcare
provider organizations
$1.9B
patient payments processed in FY20
Who we are: Leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care
$125M
revenue in FY20
25% revenue
growth in FY20
What we do: Enable healthcare provider organizations to optimize
~$7B total
addressable market
Leadership in large, underpenetrated and growing market with strong tailwinds Proven ability to innovate and meet the evolving needs of our clients
INVESTMENT HIGHLIGHTS
4
Leading SaaS platform for patient intake and experience with integrated patient payments Attractive, highly scalable financial model Significant and measurable return on investment Founder-led and deeply experienced management team with strong culture Multiple growth opportunities
ATTRACTIVE INDUSTRY TAILWINDS
5
Wasteful Spending Increasing Patient Responsibility Increasing Consumerism Shift to Value-Based Care Models
pocket spend by 2027
46% of health plan market2
collect only half of patient balances after initial visit
quality care, cost transparency, shared decision making and convenience
use online reviews as first step in physician search
shift to incentivize value and quality
robust data, sophisticated payment-attribution capabilities and substantive patient engagement
Focus on Personalized Healthcare Solutions
reach patients when making care decisions
strategies not as effective as targeted outreach
healthcare spend1
healthcare waste1
related waste1
1 In 2018 2 As of the first half of 2018OUR VALUE PROPOSITION AND HOW WE MAKE MONEY
6
Providers
staff efficiency
profitability
charged on a per provider per month basis (PMPM)
applications elected
Patients
fees
volume processed through Phreesia Platform
Life Sciences Companies
adherence
marketing solutions to life sciences companies
engagements with target audiences Value proposition How we make money
Staff Use These:
IN THE OFFICE Phreesia Dashboard AT HOME, ON THE GO, IN THE OFFICE Mobile IN THE OFFICE PhreesiaPad Arrivals Station
Patients Use These:
IN THE OFFICE Analytics
OUR END-TO-END PATIENT INTAKE SOLUTION
7
Real-time Integration
Electronic Medical Record Practice Management System Practice Data Warehouses APIs Payment Networks Payers Telehealth Vendors
THE PHREESIA PLATFORM
Robust analytic tools Commitment to privacy and security Reliable and scalable platform Real-time integration with leading PMs and EMRs
Patient Intake Platform
Appointments
Online appointment requests Referrals Appointments queue to track requests
Revenue Cycle
Insurance verification POS payments Card on file Payment plans Online payments
Clinical Support
Clinical screening tools and PROs for 25+ specialties Behavioral health screenings for primary care
Patient Activation Registration
Social determinants
Mobile PhreesiaPads Consent management Payment assurance
8
Patient surveys Branded patient announcements Health campaigns Automated self- scheduling
Flexible APIs
8
Intake Workflows Arrivals Kiosks Typical entry-level package Patient chat
Life Sciences
Patient Connect Patient Insights Advanced Analytics
OUR CURRENT AMBULATORY-BASED ADDRESSABLE MARKET
TAM of ~$7B
Source: (1) Kaiser Family Foundation, BLS Data, American Association of Nurse Practitioners, National Commission of Certification of Physician Assistants - assumes ~1,005,000 total physicians , with ~75% in non-acute care setting and 100% taking appointments; ~165,000 NPs, with ~85% in non-acute care setting and ~55% taking appointments; 90,000 PAs, with ~60% in non-acute care setting and ~65% taking appointments; (2) CMS, includes out-of-pocket spending for physician, clinical and other professional services; (3) ZS Associates, projected spending in point-of-care marketing in pharma (2014 – 2020)
~890K addressable providers1
in United States
Subscription-Based Revenue
$4.3B
$91B addressable out-of-pocket2
in United States
Consumer-Related Transaction And Payment Processing Fees
$2.2B
Life Sciences DTC point-of-care marketing spend3
$750M
9
Current addressable market does not include acute care
~780K active physicians ~77K nurse practitioners ~35K physician assistants
SCALABLE FROM SMALL BUSINESSES TO LARGE ENTERPRISES
10
Serving ~1,600 healthcare provider organizations 25+ medical specialties of varying sizes Serving 13 of the top 20 global pharma companies
Providers Life Sciences
Physician groups Health systems Pharma manufacturers ~40 life sciences brands
manufacturer
manufacturer
z
In its annual “Best in KLAS: Software and Services” report, KLAS named Phreesia the 2020 Best in KLAS for Patient intake Management, based on survey data from provider groups on areas such as integration, implementation support and overall customer satisfaction. This is the second year that KLAS has named a top patient intake solution. Phreesia was also the top-ranked solution last year.
Phreesia Is the 2020 Best in KLAS Patient Intake Management Solution
11
MULTIPLE GROWTH OPPORTUNITIES
12
early innings
providers
within existing clients
within existing sites
continuously innovate
Cost Estimation and Mobile
applications
and new and larger clients highly scalable on existing platform
in FY19 and FY20
partnerships (i.e. PM, EHR, Life Sciences, R1)
acquisition completed in FY19
Land new clients Grow footprint within existing clients Cross-sell new applications to existing clients Margin expansion through scale Partnerships and M&A
WATCH THE VIDEO BY CLICKING BELOW
13
14
FINANCIAL PERFORMANCE HIGHLIGHTS
15
Growth Opportunities Highly Visible Revenue Attractive Economics
SCALABLE AND PREDICTABLE SOURCES OF REVENUE
16
Phreesia payment facilitator model
transactions to other payment processors
Subscription and related services1 Payment processing fees
patients of existing and new providers / clients
37% 45%
REVENUE MODEL DRIVERS FY20 % REV
Life Sciences
products represent upside potential
18%
1 In addition to subscription revenue, Phreesia generates certain fees from provider clients for professional services associated with implementation, travel and expense reimbursements, shipping and handling, sale of hardware(PhreesiaPads and Arrivals Stations), on-site support and training
Strong visibility into revenue at the beginning of the fiscal period based on contracted business
Provider
1,490 1,571 1,549 1,632 FY 19 FY 20 FQ1 20 FQ1 21
+5%
$4 $6 $24 $27
FQ1 20 FQ1 21
$19 $22 $81 $103
FY 19 FY 20
STRONG OPERATING AND FINANCIAL PERFORMANCE
17
TOTAL REVENUE ($M)
FY ended January 31
$100 $125
+25%
Provider Life Sciences
1 For a reconciliation to the nearest GAAP measure, please see slide 20$28 $33 $3.5 $4.8 ($0.3) $1.5 FY 19 FY 20 FQ1 20 FQ1 21
PROVIDER CLIENTS
REVENUE PER CLIENT ($K) $54,231 $65,486 FY 19 FY 20 $15,649 $16,735 FQ1 20 FQ1 21
+18% +5% +21% +7%
+27% +13%
18
DETAILED INCOME STATEMENT
19
1 For a reconciliation to the nearest GAAP measure, please see slide 20$M Fiscal year ended January 31, Three months ended April 30, FY 2019 FY 2020 Q1 2020 Q1 2021 Revenue: Subscription and Related Services Revenue $43.9 $56.4 $12.7 $15.6 Payment Processing Revenue 36.9 46.5 11.6 11.7 Total Provider Revenue $80.8 $102.9 $24.2 $27.3 Life Sciences $19.1 $21.9 $4.1 $6.1 Total Revenue $99.9 $124.8 $28.3 $33.4 % Growth 25% 25% 19% 18% Expenses: Cost of revenues (excl. depreciation and amortization) $15.1 $16.8 $4.0 $4.7 Payment Processing Expense 21.9 27.9 6.9 6.8 Sales and Marketing 26.4 32.4 7.7 9.4 Research and Development 14.3 18.6 4.3 5.0 General and Adminstrative 20.1 30.5 6.2 8.7 Depreciation 7.6 8.8 2.2 2.3 Amortization 4.0 5.2 1.2 1.4 Total Expenses $109.4 $140.1 $32.6 $38.4 Operating loss ($9.5) ($15.3) ($4.3) ($5.0) Operating Margin (9.5%) (12.3%) (15.0%) (14.9%) Other Income (Expense) ($0.0) ($1.0) (1.1) (0.7) Change in Fair Value of Warrant Liability (2.1) (3.3) (0.4) 0.0 Interest Income (Expense) (3.5) (2.4) (0.8) (0.3) Total Other Income (Loss) ($5.6) ($6.8) ($2.4) ($1.0) (Benefit From) Provision for Taxes 0.0 (1.8) 0.1 0.1 Net Income (Loss) ($15.1) ($20.3) ($6.7) ($6.1) Net Margin % (15.1%) (16.3%) (23.6%) (18.3%) Memo: Adjusted EBITDA 1 $3.5 $4.8 ($0.3) $1.5 % Margin 3.6% 3.8% (1.0%) 4.6%
ADJUSTED EBITDA RECONCILIATION1
20
1 Adjusted EBITDA is a supplemental measure of our performance that is not required by, or presented in accordance with, GAAP. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not beconsidered as an alternative to net income or loss or any other performance measure derived in accordance with GAAP, or as an alternative to cash flows from operating activities as a measure of our liquidity
$M Fiscal year ended January 31, Three months ended April 30, FY 2019 FY 2020 Q1 2020 Q1 2021 Reconciliation to Adjusted EBITDA Net Income (Loss) ($15.1) ($20.3) ($6.7) ($6.1) Interest Income (Expense) 3.5 2.4 0.8 0.3 Depreciation and Amortization 11.6 13.9 3.4 3.6 Stock-Based Compensation Expense 1.4 6.2 0.6 2.9 (Benefit From) Provision for Taxes 0.0 (1.8) 0.1 0.1 Change in Fair Value of Warrant Liability 2.1 3.3 0.4 0.0 Other (Income) Expense 0.0 1.0 1.1 0.7 Adjusted EBITDA1 $3.5 $4.8 ($0.3) $1.5 Adjusted EBITDA Margin % 3.6% 3.8% (1.0%) 4.6%